FDA Tentative Approval for Omcazio: A New Cabozantinib Capsule Formulation

Handa Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to Omcazio (cabozantinib) capsules, a novel alternate-salt formulation of the well-established tyrosine kinase inhibitor (TKI).

Developed under the Section 505(b)(2) regulatory pathway, Omcazio represents a pharmacological evolution of cabozantinib. Unlike current formulations, this capsule is engineered to improve drug absorption and has demonstrated no clinically significant food effect in bioavailability studies. While a tentative approval indicates the product meets all safety, effectiveness, and manufacturing quality standards, the drug is not yet available for commercial distribution in the United States pending final regulatory steps.

Broad Clinical Indications

The tentative approval for Omcazio covers several high-priority oncologic indications where cabozantinib is already a standard of care:

• Advanced Renal Cell Carcinoma (RCC): Indicated as a single agent for adult patients and as a first-line treatment in combination with the immunotherapy agent nivolumab.
• Hepatocellular Carcinoma (HCC): Indicated for adult patients previously treated with sorafenib.
• Extra-pancreatic Neuroendocrine Tumors (epNET): Indicated for adult and pediatric patients (aged 12 and older) with previously treated, unresectable, locally advanced or metastatic, well-differentiated tumors.

Medication Safety and Dosing Conversion

For oncology nurses, the most vital takeaway from this announcement involves medication safety and dosage conversion. Omcazio is bioequivalent to Cabometyx at a significantly lower dose. Consequently, the FDA has included a Boxed Warning regarding the risk of serious adverse reactions or reduced effectiveness if medication errors occur during product substitution.

Omcazio is not substitutable on a milligram-to-milligram basis with other cabozantinib products. Clinical staff must verify the specific brand and intended dosage before dispensing to avoid toxicity or treatment failure. The recommended conversion between Cabometyx tablets and Omcazio capsules is as follows:

• 60 mg Cabometyx once daily converts to 34.5 mg Omcazio once daily.
• 40 mg Cabometyx once daily converts to 23 mg Omcazio once daily.
• 20 mg Cabometyx once daily converts to 11.5 mg Omcazio once daily.

Safety Profile and Adverse Reaction Management

The safety profile of Omcazio aligns with the known side effects of cabozantinib. Common adverse reactions occurring in at least 20% of patients receiving Omcazio as a single agent include diarrhea, fatigue, palmar-plantar erythrodysesthesia (PPE), decreased appetite, hypertension, and nausea.

When used in combination with nivolumab, nurses should be alert for increased frequencies of hepatotoxicity (elevated ALT/AST) and adrenal insufficiency. Management strategies include interrupting treatment for severe diarrhea or PPE until symptoms improve to Grade 1 or resolve, and regular blood pressure monitoring for hypertension.

Additionally, Omcazio carries risks related to hemorrhage, gastrointestinal perforations, and fistulas. For patients undergoing surgery, Omcazio must be withheld for at least three weeks prior to elective procedures and invasive dental work to prevent impaired wound healing or osteonecrosis of the jaw.

Key Takeaways for Oncology Nurses

• Tentative Approval Status: Omcazio meets FDA standards but is not yet available for prescription.
• Alternate-Salt Benefits: The formulation is designed for improved absorption and can be taken with or without food, potentially improving patient adherence and lifestyle flexibility.
• Lower Bioequivalent Dosing: Omcazio requires a lower numerical dose than Cabometyx to achieve the same therapeutic effect.
• Combination Therapy: In RCC, the drug is indicated for use alongside nivolumab, necessitating dual-agent monitoring for immune-related adverse events.
• Pediatric Inclusion: The indication for epNET extends to patients as young as 12 years old.

References

1. Handa Oncology receives FDA tentative approval for Omcazio (cabozantinib) capsules. BioSpace. Published July 31, 2026. Accessed July 31, 2026. https://www.biospace.com/press-releases/handa-oncology-receives-fda-tentative-approval-for-omcazio-cabozantinib-capsules